Analyst Jason Butler of JMP Securities reiterated a Buy rating on Precigen (PGEN – Research Report), with a price target of $7.00. Jason ...
Wave Life Sciences (WVE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 12. Analyst ...
Urogen's UGN-102 presents a $5B market opportunity for bladder cancer treatment, despite risks. Read more about URGN stock ...
The U.S. Food and Drug Administration has proposed removing oral phenylephrine, widely used in cold and cough syrups, as an active ingredient in over-the-counter drugs for nasal congestion, stating it ...
Shares of Altimmune (NASDAQ:ALT) rallied 30% in afternoon trading after the company issued several business updates along ...
With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says
FDA clears iRhythm's first 510(k ... The analyst maintains the Outperform rating on iRhythm Technologies stock. Price Action: IRTC stock is up 20.30% at $74.70 at last check Tuesday.
Denali Therapeutics (NASDAQ:DNLI) said it plans to file for FDA accelerated approval of its ... to nearly $1.3B by 2029 ...
Rhythm Technologies (Nasdaq:IRTC) announced that the FDA granted 510(k) clearance for Zio AT design modifications and ...
On Tuesday, Citi reaffirmed its Sell rating and a $26.00 stock price target for NASDAQ:PTCT, PTC Therapeutics (NASDAQ:PTCT). The focus of this confirmation was the U.S. Food and Drug Administration's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback